Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Риск тромбоэмболических событий у пациенток, принимающих комбинированные оральные контрацептивы и заместительную гормональную терапию, а также методы их профилактики: обзор литературы
Риск тромбоэмболических событий у пациенток, принимающих комбинированные оральные контрацептивы и заместительную гормональную терапию, а также методы их профилактики: обзор литературы
Сурикова Н.А., Глухова А.С., Кравченко Е.Е., Вишняков В.А., Мокин Е.И. Риск тромбоэмболических событий у пациенток, принимающих комбинированные оральные контрацептивы и заместительную гормональную терапию, а также методы их профилактики: обзор литературы // CardioСоматика. 2025. Т. 16, № 2. С. 168–175. DOI: 10.17816/CS640894 EDN: TMQHIG
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В настоящее время риск тромбоэмболических осложнений при приёме комбинированных оральных контрацептивов (КОК) и заместительной гормональной терапии может вызывать опасения как у врачей, так и у пациентов. Целью работы был анализ имеющихся данных о приёме КОК и риске развития тромбоэмболии. В обзоре представлены материалы отечественных и зарубежных авторов, которые проводили исследования у женщин, принимающих КОК и сталкивающихся с тромбоэмболическими осложнениями. Для написания статьи использовано 37 различных источников литературы — статьи, опубликованные в международных базах цитирования PubMed (MEDLINE), Scopus, а также размещённые в РИНЦ фундаментальные исследования, монографии. Отбор данных осуществляли по ключевым словам: «сердечно-сосудистые заболевания», «комбинированные оральные контрацептивы», «КОК», «тромбоэмболия лёгочной артерия», «ТЭЛА», «инфаркт миокарда». Из анализа исключали материалы, авторство которых не установлено, учебные пособия, околонаучные интернет-ресурсы, а также не соответствующие тематике исследования.
По результатам обзора выявлено, что применение КОК может влиять на риск развития тромбоэмболии лёгочной артерии (ТЭЛА), однако стоит учитывать, что на образование тромбов влияют и другие факторы. Некоторые исследования показывают, что использование КОК третьего и четвёртого поколений может увеличивать риск развития ТЭЛА, однако этот риск всё равно остаётся относительно невысоким. Важно отметить, что решение о применении КОК и выборе конкретного препарата должно приниматься врачом на основе индивидуальных особенностей пациентки, её медицинской истории и факторов риска. Необходимо помнить, что отказ от КОК не гарантирует полного отсутствия риска развития ТЭЛА, так как на него влияют и другие факторы, такие как наследственность, образ жизни, наличие других заболеваний и т.д.
Ключевые слова: факторы риска, комбинированные оральные контрацептивы, тромбоэмболия лёгочной артерии, сердечно-сосудистые заболевания
The review revealed that the use of COCs may influence the risk of developing pulmonary embolism (PE); however, thrombus formation is also affected by additional factors. Some studies suggest that third- and fourth-generation COCs may be associated with a higher risk of PE, although the absolute risk remains relatively low. It is important to emphasize that the decision to initiate COC use and the selection of a specific drug should be made by a physician based on the patient’s individual characteristics, medical history, and risk factors. Notably, discontinuation of COCs does not eliminate the risk of PE entirely, as hereditary predisposition, lifestyle, and comorbid conditions may also contribute.
Keywords: risk factors, combined oral contraceptives, pulmonary embolism, cardiovascular diseases
По результатам обзора выявлено, что применение КОК может влиять на риск развития тромбоэмболии лёгочной артерии (ТЭЛА), однако стоит учитывать, что на образование тромбов влияют и другие факторы. Некоторые исследования показывают, что использование КОК третьего и четвёртого поколений может увеличивать риск развития ТЭЛА, однако этот риск всё равно остаётся относительно невысоким. Важно отметить, что решение о применении КОК и выборе конкретного препарата должно приниматься врачом на основе индивидуальных особенностей пациентки, её медицинской истории и факторов риска. Необходимо помнить, что отказ от КОК не гарантирует полного отсутствия риска развития ТЭЛА, так как на него влияют и другие факторы, такие как наследственность, образ жизни, наличие других заболеваний и т.д.
Ключевые слова: факторы риска, комбинированные оральные контрацептивы, тромбоэмболия лёгочной артерии, сердечно-сосудистые заболевания
________________________________________________
The review revealed that the use of COCs may influence the risk of developing pulmonary embolism (PE); however, thrombus formation is also affected by additional factors. Some studies suggest that third- and fourth-generation COCs may be associated with a higher risk of PE, although the absolute risk remains relatively low. It is important to emphasize that the decision to initiate COC use and the selection of a specific drug should be made by a physician based on the patient’s individual characteristics, medical history, and risk factors. Notably, discontinuation of COCs does not eliminate the risk of PE entirely, as hereditary predisposition, lifestyle, and comorbid conditions may also contribute.
Keywords: risk factors, combined oral contraceptives, pulmonary embolism, cardiovascular diseases
Полный текст
Список литературы
1. Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363–2371. doi: 10.1161/ATVBAHA.114.304488 EDN: USAIDF
2. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14. doi: 10.1007/s11239-015-1311-6
3. Patel KV, Pandey A, de Lemos JA. Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. Circulation. 2018;137(24):2551–2553. doi: 10.1161/CIRCULATIONAHA.118.035289
4. Rashidi HH, Tran NK, Betts EV, et al. Machine learning in the coagulation and hemostasis arena: an overview and evaluation of methods, review of literature, and future directions. J Thromb Haemost. 2023;21(4):728–743. doi: 10.1016/j.jtha.2023.01.001 EDN: YYBTFX
5. Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716–799. doi: 10.1093/eurheartj/ehab892 EDN: YHSYOD
6. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. doi: 10.1093/eurheartj/ehz405 EDN: QGDIKF
7. Mirabelli MH, Devine MJ, Singh J, Mendoza M. The Preparticipation Sports Evaluation. Am Fam Physician. 2015;92(5): 371–376.
8. Nishat S, Jafry AT, Martinez AW, Awan FR. Paper-based microfluidics: Simplified fabrication and assay methods. Sens Actuators B Chem. 2021;336:129681. doi: 10.1016/j.snb.2021.129681 EDN: DMEMMZ
9. United Nations: Department of Economic and Social Affairs. Contraceptive Use by Method 2019: Data Booklet. United Nations, 2020. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/20... Accessed: 25.08.2024
10. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2015;350:h2135. doi: 10.1136/bmj.h2135
11. Douxfils J, Raskin L, Didembourg M, et al. Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis. Front Endocrinol. 2024;15:1428597. doi: 10.3389/fendo.2024.1428597 EDN: IEKCSS
12. Liau SY, Read DC, Pugh WJ, et al. Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ions. Lett Appl Microbiol. 1997;25(4):279–283. doi: 10.1046/j.1472-765X.1997.00219.x
13. Cauci S, Xodo S, Buligan C, et al. Oxidative Stress Is Increased in Combined Oral Contraceptives Users and Is Positively Associated with High‑Sensitivity C-Reactive Protein. Molecules. 2021;26(4):1070. doi: 10.3390/molecules26041070 EDN: ACTJIC
14. Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol. 2016;67(6):712–723. doi: 10.1016/j.jacc.2015.11.037 EDN: UOCFSL
15. Nikolay E, Alexey M, Ivan B, Ilya Z. Self-propagating high-temperature synthesis of high-entropy ceramic composition (Hf0.25Ti0.25Cr0.25(FeV)0.25). N Mater Lett. 2023;346:134562. doi: 10.1016/j.matlet.2023.134562
16. Manzoor S, Ganie MA, Majid S, et al. Analysis of Intrinsic and Extrinsic Coagulation Pathway Factors in OCP Treated PCOS Women. Indian J Clin Biochem. 2021;36(3):278–287. doi: 10.1007/s12291-020-00901-w EDN: FSMECF
17. Oslakovic S, Zadro R. Comparison of the Impact of Four Generations of Progestins on Hemostatic Variables. Clin Appl Thromb Hemost. 2014;20(4):448–455. doi: 10.1177/1076029612463426
18. Asubiaro J. The Impact of Hormonal Contraceptives on the Incidence and Progression of Cardiovascular Diseases in Women: A Systematic Review. Cureus. 2024;16(7):e65366. doi: 10.7759/cureus.65366 EDN: NTBOXU
19. Barcellona D, Grandone E, Marongiu F. Hormones and thrombosis: the dark side of the moon. Blood Transfus. 2024;22(1):46–54. doi: 10.2450/BloodTransfus.535
20. Meaidi A, Mascolo A, Sessa M, et al. Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study. BMJ. 2023;382:e074450. doi: 10.1136/bmj-2022-074450 EDN: VFKNFC
21. Bird ST, Hartzema AG, Brophy JM, et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185(2):E115–E120. doi: 10.1503/cmaj.120677
22. Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016;353:i2002. doi: 10.1136/bmj.i2002
23. Dhanjal MK. Contraception in women with medical problems. Obstet Med. 2008;1(2):78–87. doi: 10.1258/om.2008.080014
24. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. Geneva: WHO, 2010. Available from: https://www.who.int/ru/publications/i/item/9789241549158 Accessed: 25.08.2024
25. Kaur S, Kidambi S, Ortega-Ribera M, et al. In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations. Cell Mol Gastroenterol Hepatol. 2023;15(3):559–571. doi: 10.1016/j.jcmgh.2022.11.008 EDN: ZVYPHS
26. Martinelli I, Lensing AWA, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127(11):1417–1425. doi: 10.1182/blood-2015-08-665927
27. Vermylen J, Hoylaerts MF. The procoagulant effects of air pollution. J Thromb Haemost. 2007;5(2):250–251. doi: 10.1111/j.1538-7836.2007.02344.x
28. Squires H, Chilcott J, Akehurst R, et al. A Framework for Developing the Structure of Public Health Economic Models. Value Health. 2016;19(5):588–601. doi: 10.1016/j.jval.2016.02.011
29. Simone B, De Stefano V, Leoncini E, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621–647. doi: 10.1007/s10654-013-9825-8 EDN: RFQYQB
30. Neumann I, Izcovich A, Aguilar R, et al. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America. Blood Adv. 2023;7(13):3005–3021. doi: 10.1182/bloodadvances.2021006534 EDN: BCZICI
31. Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700. doi: 10.1016/j.contraception.2016.04.014
32. Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception. 2016;94(6):590–604. doi: 10.1016/j.contraception.2016.05.014
33. Dulicek P, Ivanova E, Kostal M, et al. Analysis of Risk Factors of Stroke and Venous Thromboembolism in Females With Oral Contraceptives Use. Clin Appl Thromb Hemost. 2018;24(5):797–802. doi: 10.1177/1076029617727857
34. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–485. doi: 10.1136/annrheumdis-2016-209770
35. Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1–126. doi: 10.15585/mmwr.rr7304a1 EDN: LYSKSA
36. Sugiura K, Ojima T, Urano T, Kobayashi T. The incidence and prognosis of thromboembolism associated with oral contraceptives: Age‑dependent difference in Japanese population. J Obstet Gynaecol Res. 2018;44(9):1766–1772. doi: 10.1111/jog.13706
37. Li J, Panucci G, Moeny D, et al. Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous‑Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database. JAMA Intern Med. 2018;178(11):1482–1488. doi: 10.1001/jamainternmed.2018.4251
38. Morimont L, Haguet H, Dogné J-M, et al. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Frontiers in Endocrinology. 2021;12:769187. doi: 10.3389/fendo.2021.769187 EDN: DIFBTG
39. de Barros VIPVL, de Oliveira ALML, do Nascimento DJ, et al. Use of hormones and risk of venous thromboembolism. Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-FPS02. doi: 10.61622/rbgo/2024FPS02 EDN: LBRXHA
2. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14. doi: 10.1007/s11239-015-1311-6
3. Patel KV, Pandey A, de Lemos JA. Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. Circulation. 2018;137(24):2551–2553. doi: 10.1161/CIRCULATIONAHA.118.035289
4. Rashidi HH, Tran NK, Betts EV, et al. Machine learning in the coagulation and hemostasis arena: an overview and evaluation of methods, review of literature, and future directions. J Thromb Haemost. 2023;21(4):728–743. doi: 10.1016/j.jtha.2023.01.001 EDN: YYBTFX
5. Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716–799. doi: 10.1093/eurheartj/ehab892 EDN: YHSYOD
6. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. doi: 10.1093/eurheartj/ehz405 EDN: QGDIKF
7. Mirabelli MH, Devine MJ, Singh J, Mendoza M. The Preparticipation Sports Evaluation. Am Fam Physician. 2015;92(5): 371–376.
8. Nishat S, Jafry AT, Martinez AW, Awan FR. Paper-based microfluidics: Simplified fabrication and assay methods. Sens Actuators B Chem. 2021;336:129681. doi: 10.1016/j.snb.2021.129681 EDN: DMEMMZ
9. United Nations: Department of Economic and Social Affairs. Contraceptive Use by Method 2019: Data Booklet. United Nations, 2020. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/20... Accessed: 25.08.2024
10. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2015;350:h2135. doi: 10.1136/bmj.h2135
11. Douxfils J, Raskin L, Didembourg M, et al. Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis. Front Endocrinol. 2024;15:1428597. doi: 10.3389/fendo.2024.1428597 EDN: IEKCSS
12. Liau SY, Read DC, Pugh WJ, et al. Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ions. Lett Appl Microbiol. 1997;25(4):279–283. doi: 10.1046/j.1472-765X.1997.00219.x
13. Cauci S, Xodo S, Buligan C, et al. Oxidative Stress Is Increased in Combined Oral Contraceptives Users and Is Positively Associated with High‑Sensitivity C-Reactive Protein. Molecules. 2021;26(4):1070. doi: 10.3390/molecules26041070 EDN: ACTJIC
14. Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol. 2016;67(6):712–723. doi: 10.1016/j.jacc.2015.11.037 EDN: UOCFSL
15. Nikolay E, Alexey M, Ivan B, Ilya Z. Self-propagating high-temperature synthesis of high-entropy ceramic composition (Hf0.25Ti0.25Cr0.25(FeV)0.25). N Mater Lett. 2023;346:134562. doi: 10.1016/j.matlet.2023.134562
16. Manzoor S, Ganie MA, Majid S, et al. Analysis of Intrinsic and Extrinsic Coagulation Pathway Factors in OCP Treated PCOS Women. Indian J Clin Biochem. 2021;36(3):278–287. doi: 10.1007/s12291-020-00901-w EDN: FSMECF
17. Oslakovic S, Zadro R. Comparison of the Impact of Four Generations of Progestins on Hemostatic Variables. Clin Appl Thromb Hemost. 2014;20(4):448–455. doi: 10.1177/1076029612463426
18. Asubiaro J. The Impact of Hormonal Contraceptives on the Incidence and Progression of Cardiovascular Diseases in Women: A Systematic Review. Cureus. 2024;16(7):e65366. doi: 10.7759/cureus.65366 EDN: NTBOXU
19. Barcellona D, Grandone E, Marongiu F. Hormones and thrombosis: the dark side of the moon. Blood Transfus. 2024;22(1):46–54. doi: 10.2450/BloodTransfus.535
20. Meaidi A, Mascolo A, Sessa M, et al. Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study. BMJ. 2023;382:e074450. doi: 10.1136/bmj-2022-074450 EDN: VFKNFC
21. Bird ST, Hartzema AG, Brophy JM, et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185(2):E115–E120. doi: 10.1503/cmaj.120677
22. Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016;353:i2002. doi: 10.1136/bmj.i2002
23. Dhanjal MK. Contraception in women with medical problems. Obstet Med. 2008;1(2):78–87. doi: 10.1258/om.2008.080014
24. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. Geneva: WHO, 2010. Available from: https://www.who.int/ru/publications/i/item/9789241549158 Accessed: 25.08.2024
25. Kaur S, Kidambi S, Ortega-Ribera M, et al. In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations. Cell Mol Gastroenterol Hepatol. 2023;15(3):559–571. doi: 10.1016/j.jcmgh.2022.11.008 EDN: ZVYPHS
26. Martinelli I, Lensing AWA, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127(11):1417–1425. doi: 10.1182/blood-2015-08-665927
27. Vermylen J, Hoylaerts MF. The procoagulant effects of air pollution. J Thromb Haemost. 2007;5(2):250–251. doi: 10.1111/j.1538-7836.2007.02344.x
28. Squires H, Chilcott J, Akehurst R, et al. A Framework for Developing the Structure of Public Health Economic Models. Value Health. 2016;19(5):588–601. doi: 10.1016/j.jval.2016.02.011
29. Simone B, De Stefano V, Leoncini E, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621–647. doi: 10.1007/s10654-013-9825-8 EDN: RFQYQB
30. Neumann I, Izcovich A, Aguilar R, et al. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America. Blood Adv. 2023;7(13):3005–3021. doi: 10.1182/bloodadvances.2021006534 EDN: BCZICI
31. Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700. doi: 10.1016/j.contraception.2016.04.014
32. Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception. 2016;94(6):590–604. doi: 10.1016/j.contraception.2016.05.014
33. Dulicek P, Ivanova E, Kostal M, et al. Analysis of Risk Factors of Stroke and Venous Thromboembolism in Females With Oral Contraceptives Use. Clin Appl Thromb Hemost. 2018;24(5):797–802. doi: 10.1177/1076029617727857
34. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–485. doi: 10.1136/annrheumdis-2016-209770
35. Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1–126. doi: 10.15585/mmwr.rr7304a1 EDN: LYSKSA
36. Sugiura K, Ojima T, Urano T, Kobayashi T. The incidence and prognosis of thromboembolism associated with oral contraceptives: Age‑dependent difference in Japanese population. J Obstet Gynaecol Res. 2018;44(9):1766–1772. doi: 10.1111/jog.13706
37. Li J, Panucci G, Moeny D, et al. Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous‑Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database. JAMA Intern Med. 2018;178(11):1482–1488. doi: 10.1001/jamainternmed.2018.4251
38. Morimont L, Haguet H, Dogné J-M, et al. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Frontiers in Endocrinology. 2021;12:769187. doi: 10.3389/fendo.2021.769187 EDN: DIFBTG
39. de Barros VIPVL, de Oliveira ALML, do Nascimento DJ, et al. Use of hormones and risk of venous thromboembolism. Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-FPS02. doi: 10.61622/rbgo/2024FPS02 EDN: LBRXHA
2. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14. doi: 10.1007/s11239-015-1311-6
3. Patel KV, Pandey A, de Lemos JA. Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. Circulation. 2018;137(24):2551–2553. doi: 10.1161/CIRCULATIONAHA.118.035289
4. Rashidi HH, Tran NK, Betts EV, et al. Machine learning in the coagulation and hemostasis arena: an overview and evaluation of methods, review of literature, and future directions. J Thromb Haemost. 2023;21(4):728–743. doi: 10.1016/j.jtha.2023.01.001 EDN: YYBTFX
5. Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716–799. doi: 10.1093/eurheartj/ehab892 EDN: YHSYOD
6. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. doi: 10.1093/eurheartj/ehz405 EDN: QGDIKF
7. Mirabelli MH, Devine MJ, Singh J, Mendoza M. The Preparticipation Sports Evaluation. Am Fam Physician. 2015;92(5): 371–376.
8. Nishat S, Jafry AT, Martinez AW, Awan FR. Paper-based microfluidics: Simplified fabrication and assay methods. Sens Actuators B Chem. 2021;336:129681. doi: 10.1016/j.snb.2021.129681 EDN: DMEMMZ
9. United Nations: Department of Economic and Social Affairs. Contraceptive Use by Method 2019: Data Booklet. United Nations, 2020. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/20... Accessed: 25.08.2024
10. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2015;350:h2135. doi: 10.1136/bmj.h2135
11. Douxfils J, Raskin L, Didembourg M, et al. Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis. Front Endocrinol. 2024;15:1428597. doi: 10.3389/fendo.2024.1428597 EDN: IEKCSS
12. Liau SY, Read DC, Pugh WJ, et al. Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ions. Lett Appl Microbiol. 1997;25(4):279–283. doi: 10.1046/j.1472-765X.1997.00219.x
13. Cauci S, Xodo S, Buligan C, et al. Oxidative Stress Is Increased in Combined Oral Contraceptives Users and Is Positively Associated with High‑Sensitivity C-Reactive Protein. Molecules. 2021;26(4):1070. doi: 10.3390/molecules26041070 EDN: ACTJIC
14. Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol. 2016;67(6):712–723. doi: 10.1016/j.jacc.2015.11.037 EDN: UOCFSL
15. Nikolay E, Alexey M, Ivan B, Ilya Z. Self-propagating high-temperature synthesis of high-entropy ceramic composition (Hf0.25Ti0.25Cr0.25(FeV)0.25). N Mater Lett. 2023;346:134562. doi: 10.1016/j.matlet.2023.134562
16. Manzoor S, Ganie MA, Majid S, et al. Analysis of Intrinsic and Extrinsic Coagulation Pathway Factors in OCP Treated PCOS Women. Indian J Clin Biochem. 2021;36(3):278–287. doi: 10.1007/s12291-020-00901-w EDN: FSMECF
17. Oslakovic S, Zadro R. Comparison of the Impact of Four Generations of Progestins on Hemostatic Variables. Clin Appl Thromb Hemost. 2014;20(4):448–455. doi: 10.1177/1076029612463426
18. Asubiaro J. The Impact of Hormonal Contraceptives on the Incidence and Progression of Cardiovascular Diseases in Women: A Systematic Review. Cureus. 2024;16(7):e65366. doi: 10.7759/cureus.65366 EDN: NTBOXU
19. Barcellona D, Grandone E, Marongiu F. Hormones and thrombosis: the dark side of the moon. Blood Transfus. 2024;22(1):46–54. doi: 10.2450/BloodTransfus.535
20. Meaidi A, Mascolo A, Sessa M, et al. Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study. BMJ. 2023;382:e074450. doi: 10.1136/bmj-2022-074450 EDN: VFKNFC
21. Bird ST, Hartzema AG, Brophy JM, et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185(2):E115–E120. doi: 10.1503/cmaj.120677
22. Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016;353:i2002. doi: 10.1136/bmj.i2002
23. Dhanjal MK. Contraception in women with medical problems. Obstet Med. 2008;1(2):78–87. doi: 10.1258/om.2008.080014
24. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. Geneva: WHO, 2010. Available from: https://www.who.int/ru/publications/i/item/9789241549158 Accessed: 25.08.2024
25. Kaur S, Kidambi S, Ortega-Ribera M, et al. In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations. Cell Mol Gastroenterol Hepatol. 2023;15(3):559–571. doi: 10.1016/j.jcmgh.2022.11.008 EDN: ZVYPHS
26. Martinelli I, Lensing AWA, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127(11):1417–1425. doi: 10.1182/blood-2015-08-665927
27. Vermylen J, Hoylaerts MF. The procoagulant effects of air pollution. J Thromb Haemost. 2007;5(2):250–251. doi: 10.1111/j.1538-7836.2007.02344.x
28. Squires H, Chilcott J, Akehurst R, et al. A Framework for Developing the Structure of Public Health Economic Models. Value Health. 2016;19(5):588–601. doi: 10.1016/j.jval.2016.02.011
29. Simone B, De Stefano V, Leoncini E, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621–647. doi: 10.1007/s10654-013-9825-8 EDN: RFQYQB
30. Neumann I, Izcovich A, Aguilar R, et al. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America. Blood Adv. 2023;7(13):3005–3021. doi: 10.1182/bloodadvances.2021006534 EDN: BCZICI
31. Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700. doi: 10.1016/j.contraception.2016.04.014
32. Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception. 2016;94(6):590–604. doi: 10.1016/j.contraception.2016.05.014
33. Dulicek P, Ivanova E, Kostal M, et al. Analysis of Risk Factors of Stroke and Venous Thromboembolism in Females With Oral Contraceptives Use. Clin Appl Thromb Hemost. 2018;24(5):797–802. doi: 10.1177/1076029617727857
34. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–485. doi: 10.1136/annrheumdis-2016-209770
35. Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1–126. doi: 10.15585/mmwr.rr7304a1 EDN: LYSKSA
36. Sugiura K, Ojima T, Urano T, Kobayashi T. The incidence and prognosis of thromboembolism associated with oral contraceptives: Age‑dependent difference in Japanese population. J Obstet Gynaecol Res. 2018;44(9):1766–1772. doi: 10.1111/jog.13706
37. Li J, Panucci G, Moeny D, et al. Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous‑Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database. JAMA Intern Med. 2018;178(11):1482–1488. doi: 10.1001/jamainternmed.2018.4251
38. Morimont L, Haguet H, Dogné J-M, et al. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Frontiers in Endocrinology. 2021;12:769187. doi: 10.3389/fendo.2021.769187 EDN: DIFBTG
39. de Barros VIPVL, de Oliveira ALML, do Nascimento DJ, et al. Use of hormones and risk of venous thromboembolism. Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-FPS02. doi: 10.61622/rbgo/2024FPS02 EDN: LBRXHA
________________________________________________
2. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14. doi: 10.1007/s11239-015-1311-6
3. Patel KV, Pandey A, de Lemos JA. Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. Circulation. 2018;137(24):2551–2553. doi: 10.1161/CIRCULATIONAHA.118.035289
4. Rashidi HH, Tran NK, Betts EV, et al. Machine learning in the coagulation and hemostasis arena: an overview and evaluation of methods, review of literature, and future directions. J Thromb Haemost. 2023;21(4):728–743. doi: 10.1016/j.jtha.2023.01.001 EDN: YYBTFX
5. Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716–799. doi: 10.1093/eurheartj/ehab892 EDN: YHSYOD
6. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. doi: 10.1093/eurheartj/ehz405 EDN: QGDIKF
7. Mirabelli MH, Devine MJ, Singh J, Mendoza M. The Preparticipation Sports Evaluation. Am Fam Physician. 2015;92(5): 371–376.
8. Nishat S, Jafry AT, Martinez AW, Awan FR. Paper-based microfluidics: Simplified fabrication and assay methods. Sens Actuators B Chem. 2021;336:129681. doi: 10.1016/j.snb.2021.129681 EDN: DMEMMZ
9. United Nations: Department of Economic and Social Affairs. Contraceptive Use by Method 2019: Data Booklet. United Nations, 2020. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/20... Accessed: 25.08.2024
10. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2015;350:h2135. doi: 10.1136/bmj.h2135
11. Douxfils J, Raskin L, Didembourg M, et al. Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis. Front Endocrinol. 2024;15:1428597. doi: 10.3389/fendo.2024.1428597 EDN: IEKCSS
12. Liau SY, Read DC, Pugh WJ, et al. Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ions. Lett Appl Microbiol. 1997;25(4):279–283. doi: 10.1046/j.1472-765X.1997.00219.x
13. Cauci S, Xodo S, Buligan C, et al. Oxidative Stress Is Increased in Combined Oral Contraceptives Users and Is Positively Associated with High‑Sensitivity C-Reactive Protein. Molecules. 2021;26(4):1070. doi: 10.3390/molecules26041070 EDN: ACTJIC
14. Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol. 2016;67(6):712–723. doi: 10.1016/j.jacc.2015.11.037 EDN: UOCFSL
15. Nikolay E, Alexey M, Ivan B, Ilya Z. Self-propagating high-temperature synthesis of high-entropy ceramic composition (Hf0.25Ti0.25Cr0.25(FeV)0.25). N Mater Lett. 2023;346:134562. doi: 10.1016/j.matlet.2023.134562
16. Manzoor S, Ganie MA, Majid S, et al. Analysis of Intrinsic and Extrinsic Coagulation Pathway Factors in OCP Treated PCOS Women. Indian J Clin Biochem. 2021;36(3):278–287. doi: 10.1007/s12291-020-00901-w EDN: FSMECF
17. Oslakovic S, Zadro R. Comparison of the Impact of Four Generations of Progestins on Hemostatic Variables. Clin Appl Thromb Hemost. 2014;20(4):448–455. doi: 10.1177/1076029612463426
18. Asubiaro J. The Impact of Hormonal Contraceptives on the Incidence and Progression of Cardiovascular Diseases in Women: A Systematic Review. Cureus. 2024;16(7):e65366. doi: 10.7759/cureus.65366 EDN: NTBOXU
19. Barcellona D, Grandone E, Marongiu F. Hormones and thrombosis: the dark side of the moon. Blood Transfus. 2024;22(1):46–54. doi: 10.2450/BloodTransfus.535
20. Meaidi A, Mascolo A, Sessa M, et al. Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study. BMJ. 2023;382:e074450. doi: 10.1136/bmj-2022-074450 EDN: VFKNFC
21. Bird ST, Hartzema AG, Brophy JM, et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185(2):E115–E120. doi: 10.1503/cmaj.120677
22. Weill A, Dalichampt M, Raguideau F, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016;353:i2002. doi: 10.1136/bmj.i2002
23. Dhanjal MK. Contraception in women with medical problems. Obstet Med. 2008;1(2):78–87. doi: 10.1258/om.2008.080014
24. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. Geneva: WHO, 2010. Available from: https://www.who.int/ru/publications/i/item/9789241549158 Accessed: 25.08.2024
25. Kaur S, Kidambi S, Ortega-Ribera M, et al. In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations. Cell Mol Gastroenterol Hepatol. 2023;15(3):559–571. doi: 10.1016/j.jcmgh.2022.11.008 EDN: ZVYPHS
26. Martinelli I, Lensing AWA, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127(11):1417–1425. doi: 10.1182/blood-2015-08-665927
27. Vermylen J, Hoylaerts MF. The procoagulant effects of air pollution. J Thromb Haemost. 2007;5(2):250–251. doi: 10.1111/j.1538-7836.2007.02344.x
28. Squires H, Chilcott J, Akehurst R, et al. A Framework for Developing the Structure of Public Health Economic Models. Value Health. 2016;19(5):588–601. doi: 10.1016/j.jval.2016.02.011
29. Simone B, De Stefano V, Leoncini E, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621–647. doi: 10.1007/s10654-013-9825-8 EDN: RFQYQB
30. Neumann I, Izcovich A, Aguilar R, et al. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America. Blood Adv. 2023;7(13):3005–3021. doi: 10.1182/bloodadvances.2021006534 EDN: BCZICI
31. Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700. doi: 10.1016/j.contraception.2016.04.014
32. Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception. 2016;94(6):590–604. doi: 10.1016/j.contraception.2016.05.014
33. Dulicek P, Ivanova E, Kostal M, et al. Analysis of Risk Factors of Stroke and Venous Thromboembolism in Females With Oral Contraceptives Use. Clin Appl Thromb Hemost. 2018;24(5):797–802. doi: 10.1177/1076029617727857
34. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–485. doi: 10.1136/annrheumdis-2016-209770
35. Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1–126. doi: 10.15585/mmwr.rr7304a1 EDN: LYSKSA
36. Sugiura K, Ojima T, Urano T, Kobayashi T. The incidence and prognosis of thromboembolism associated with oral contraceptives: Age‑dependent difference in Japanese population. J Obstet Gynaecol Res. 2018;44(9):1766–1772. doi: 10.1111/jog.13706
37. Li J, Panucci G, Moeny D, et al. Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous‑Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database. JAMA Intern Med. 2018;178(11):1482–1488. doi: 10.1001/jamainternmed.2018.4251
38. Morimont L, Haguet H, Dogné J-M, et al. Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk. Frontiers in Endocrinology. 2021;12:769187. doi: 10.3389/fendo.2021.769187 EDN: DIFBTG
39. de Barros VIPVL, de Oliveira ALML, do Nascimento DJ, et al. Use of hormones and risk of venous thromboembolism. Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-FPS02. doi: 10.61622/rbgo/2024FPS02 EDN: LBRXHA
Авторы
Н.А. Сурикова*1, А.С. Глухова2, Е.Е. Кравченко1, В.А. Вишняков1, Е.И. Мокин1
1Оренбургский государственный медицинский университет, Оренбург, Россия;
2Медицинский центр «Одонт», Санкт-Петербург, Россия
*nina70494@mail.ru
1Orenburg State Medical University, Orenburg, Russia;
2Odont Medical Center, Saint Petersburg, Russia
*nina70494@mail.ru
1Оренбургский государственный медицинский университет, Оренбург, Россия;
2Медицинский центр «Одонт», Санкт-Петербург, Россия
*nina70494@mail.ru
________________________________________________
1Orenburg State Medical University, Orenburg, Russia;
2Odont Medical Center, Saint Petersburg, Russia
*nina70494@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.